A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice

There is an unmet need for monoclonal antibodies (mAbs) for prevention or as adjunctive treatment of herpes simplex virus (HSV) disease. Most vaccine and mAb efforts focus on neutralizing antibodies, but for HSV this strategy has proven ineffective. Preclinical studies with a candidate HSV vaccine s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuraoka, Masayuki, Aschner, Clare Burn, Windsor, Ian W., Mahant, Aakash Mahant, Garforth, Scott J., Kong, Susan Luozheng, Achkar, Jacqueline M., Almo, Steven C., Kelsoe, Garnett, Herold, Betsy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888390/
https://www.ncbi.nlm.nih.gov/pubmed/36454639
http://dx.doi.org/10.1172/JCI161968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9888390/
https://www.ncbi.nlm.nih.gov/pubmed/36454639
http://dx.doi.org/10.1172/JCI161968

Ejemplares similares